Century Therapeutics Shares Hit 52-Week High After Private Placement Deal

Dow Jones

Jan 08

By Chris Wack

Century Therapeutics shares were 37% higher, at $1.78, after the company said it has entered into a securities-purchase agreement for a private placement for initial gross proceeds of about $135 million.

The stock hit its 52-week high of $1.80 earlier in the session, and is up 64% in the past 12 months.

The Philadelphia-based biotechnology company on Thursday said the financing is being led by new investor TCGX and includes participation from additional new and existing investors, including RA Capital Management, Commodore Capital, and Deep Track Capital.

The private placement is expected to close Friday.

Century Therapeutics said it will issue about 117.4 million shares and accompanying warrants to buy 58.7 million shares in the private placement at $1.15 per share and accompanying warrant.

Century said it intends to use the proceeds from the private placement to fund development of its lead product candidate, CNTY-813, and for working capital and other general corporate purposes.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

January 08, 2026 10:06 ET (15:06 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2601393120"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601393120\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601393120?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601393120","market":"fut","top_or_hot":-1,"title":"Century Therapeutics Shares Hit 52-Week High After Private Placement Deal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Century <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares were 37% higher, at $1.78, after the company said it has entered into a securities-purchase agreement for a private placement for initial gross proceeds of about $135 million. \n</p>\n<p>\n  The stock hit its 52-week high of $1.80 earlier in the session, and is up 64% in the past 12 months. \n</p>\n<p>\n  The Philadelphia-based biotechnology company on Thursday said the financing is being led by new investor TCGX and includes participation from additional new and existing investors, including RA Capital Management, Commodore Capital, and Deep Track Capital. \n</p>\n<p>\n  The private placement is expected to close Friday. \n</p>\n<p>\n  Century Therapeutics said it will issue about 117.4 million shares and accompanying warrants to buy 58.7 million shares in the private placement at $1.15 per share and accompanying warrant. \n</p>\n<p>\n  Century said it intends to use the proceeds from the private placement to fund development of its lead product candidate, CNTY-813, and for working capital and other general corporate purposes. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 10:06 ET (15:06 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Century Therapeutics Shares Hit 52-Week High After Private Placement Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCentury Therapeutics Shares Hit 52-Week High After Private Placement Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-08 23:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Century <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares were 37% higher, at $1.78, after the company said it has entered into a securities-purchase agreement for a private placement for initial gross proceeds of about $135 million. \n</p>\n<p>\n  The stock hit its 52-week high of $1.80 earlier in the session, and is up 64% in the past 12 months. \n</p>\n<p>\n  The Philadelphia-based biotechnology company on Thursday said the financing is being led by new investor TCGX and includes participation from additional new and existing investors, including RA Capital Management, Commodore Capital, and Deep Track Capital. \n</p>\n<p>\n  The private placement is expected to close Friday. \n</p>\n<p>\n  Century Therapeutics said it will issue about 117.4 million shares and accompanying warrants to buy 58.7 million shares in the private placement at $1.15 per share and accompanying warrant. \n</p>\n<p>\n  Century said it intends to use the proceeds from the private placement to fund development of its lead product candidate, CNTY-813, and for working capital and other general corporate purposes. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 10:06 ET (15:06 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2601393120","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601393120","pubTimestamp":1767884760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Century Therapeutics shares were 37% higher, at $1.78, after the company said it has entered into a securities-purchase agreement for a private placement for initial gross proceeds of about $135 million.The stock hit its 52-week high of $1.80 earlier in the session, and is up 64% in the past 12 months.The Philadelphia-based biotechnology company on Thursday said the financing is being led by new investor TCGX and includes participation from additional new and existing investors, including RA Capital Management, Commodore Capital, and Deep Track Capital.The private placement is expected to close Friday.Century Therapeutics said it will issue about 117.4 million shares and accompanying warrants to buy 58.7 million shares in the private placement at $1.15 per share and accompanying warrant.Century said it intends to use the proceeds from the private placement to fund development of its lead product candidate, CNTY-813, and for working capital and other general corporate purposes.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IPSC":"Century Therapeutics, Inc.","BK4505":"高瓴资本持仓","BK4539":"次新股"},"translate_title":"私募交易后Century Therapeutics股价触及52周高点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPSC":1.5},"content_text":"By Chris Wack \n\n\n \n\n\n  Century Therapeutics shares were 37% higher, at $1.78, after the company said it has entered into a securities-purchase agreement for a private placement for initial gross proceeds of about $135 million. \n\n\n  The stock hit its 52-week high of $1.80 earlier in the session, and is up 64% in the past 12 months. \n\n\n  The Philadelphia-based biotechnology company on Thursday said the financing is being led by new investor TCGX and includes participation from additional new and existing investors, including RA Capital Management, Commodore Capital, and Deep Track Capital. \n\n\n  The private placement is expected to close Friday. \n\n\n  Century Therapeutics said it will issue about 117.4 million shares and accompanying warrants to buy 58.7 million shares in the private placement at $1.15 per share and accompanying warrant. \n\n\n  Century said it intends to use the proceeds from the private placement to fund development of its lead product candidate, CNTY-813, and for working capital and other general corporate purposes. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 10:06 ET (15:06 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}